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Aim: To evaluate potential of Naphthal-NU, Napro-NU and 5-Nitro-naphthal-NU, 2-chloroethylnitrosourea compounds with 
substituted naphthalimide in the pre-clinical studies. Materials and Methods: In vitro cytotoxicity of three nitrosoureas was deter-
mined in human and mouse tumor cell lines by MTT assays. In vivo anti-tumor potential was evaluated in Sarcoma-180 (S-180) 
and Ehrlich’s carcinoma (EC) solid tumors. Apoptosis in S-180 cells was analyzed by using Annexin V-Propidium Iodide (PI). 
Histological analysis of liver and kidney was performed at optimum dose (50 mg/kg). Expression status of CD4+, CD8+ and CD25+ 
cells in treated mouse were also examined. Results: Significant tumor growth retardation by the compounds was noted in early and 
advanced disease groups, as the life span of drug treated mice increased considerably. Drug induced killing was observed by induc-
tion of apoptosis. Naphthal-NU and 5-Nitro-naphthal-NU were effective to normalize the tumor induced structural abnormalities 
of liver and kidney. The compounds have no immunotoxic effect on CD4+ and CD8+ T cells and down regulate CD4+CD25+ regu-
latory T cells. Conclusion: Overall data holds promise for the antitumor activity with lower toxicity of the compounds that can 
be utilized for the treatment of human malignant tumors.
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Development of an anticancer compound is al-
ways a fascinating challenge in the field of cancer re-
search [1]. Chloroethylnitrosoureas are a group 
of anticancer agents with a high demonstrated activity 
against a variety of hematological malignancies and 
solid tumors, especially Hodgkin’s disease, small cell 
carcinoma of the lung and glioma, however, clinical use 
rather limited due to their delayed and cumulative he-
matological toxicity [2]. Chloroethylnitrosoureas, such 
as CCNU, Me-CCNU (Fig. 1; Structure A), BCNU, etc., 
are chemotherapeutic agents of most interest for treat-
ment of malignant melanoma. The rationale of choo-
sing naphthalimide moiety is because some of them 
as Mitonafide and Amonafide (Fig. 1; Structure B) 
are DNA binder and possess excellent anti-tumor 
activities [3, 4]. Based on the above logic, we choose 
the naphthalimide ring residue as the carrier mole-
cule for the NU group. It was reported earlier that 
Nap-NU, 2-[2-{3-(2-Chloroethyl)-3-nitrosoureido}
ethyl]-1H-benz[de]isoquinoline-1,3-dione, Napro-
NU, 2-[3{3-(2-Chloroethyl)-3-nitrosoureido}propyl]-
1H-benz[de]isoquinoline-1,3-dione and 5-NO2-Nap-
NU, 5-Nitro-2-[2{(2-chloroethyl)-3-nitrosoureido}
ethyl]-1H-benz[de]iso-quinoline-1,3-dione (Fig. 1; 
Structure C), rationally designed naphthalimides 
based mixed function nitrosourea, possessed in vivo 
anticancer activity in murine ascites tumors namely 
Sarcoma-180 (S-180) and Ehrlich’s carcinoma 
(EC) [5–9].
R = H, CCNU
   = Me, Me-CCNU
R = NO2, Mitonaﬁde
   = NH2, Amonaﬁde
Structure A Structure B
Structure C
Naphthal-NU: X=Cl, R=H
5-Nitro-naphthal-NU: X=Cl, R=5-NO2
Napro-NU: X=Cl, R=H
Fig. 1. Chemical structures
In this context, present study was designed 
to develop further, an interesting group of anti-cancer 
agents as 2-chloroethylnitrosourea derivatives of sub-
stituted naphthalimides like Nap-NU, Napro-NU and 
5-NO2-Nap-NU. It aims towards the in vitro cytotoxic 
potential of three derivatives in different human and 
mouse tumor cell lines. In vivo anti-tumor activities 
of the compounds were also tested on mouse solid 
tumors (sarcoma and carcinoma). Apoptotic potential 
was determined on S-180 cells and drug toxicity was 
assessed in normal and tumor bearing mice. Com-
parison with established anti-cancer drugs suggested 
that potential of Nap-NU, Napro-NU and 5-NO2-Nap-
NU as an anti-cancer agent may be critically examined 
for their entry in clinical settings.
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MATERIALS AND METHODS
Drug. Nap-NU, Napro-NU and 5-NO2-Nap-
NU were prepared as reported earlier from Chitta-
ranjan National Cancer Institute (CNCI) [5–9]. It was 
characterized by 1HNMR spectra in CDCl3. Purity 
of compound was checked by HPLC [Waters modular 
system, Millford, USA; (μ-bondapak C18 steel column, 
30 cm×3.9 mm), isocratic mobile phase — methanol: 
water (v:v, 1:1) at a flow rate of 0.5 ml/min expressed 
in retention time (R.T.); UV detection at 254 nm; data 
analysis with Empower 1154 Software] at room tem-
perature [5–9]. Anticancer drugs were purchased from 
Sigma-Aldrich Com. (USA).
Mice, animal treatment and tumor cells. Swiss 
albino male mice of about 6–8 weeks of age and 
weighting 24 ± 2 g were taken. Animals were randomly 
bred in the vivarium of CNCI housed in cage and main-
tained on standard mouse food and tap water ad libi-
tum. All in vivo experiments were conducted following 
the guidelines of IAEC (Institutional Animal Ethical 
Committee) approved by CPCSEA (Committee for the 
Purpose of Control and Supervision of Experiments 
on Animals). Physiological saline containing 2% Tween 
20 (Sigma Inc., USA) was used for drug administra-
tion in respective doses through intraperitoneal (i.p.) 
route to each mouse in different schedules. The drug 
solutions were prepared daily just prior to the injec-
tion. The control groups received an equal volume 
of vehicle (0.2 ml) on those days. The number of death 
was monitored daily during the test. S-180, EC and 
Dalton’s lymphoma (DL-60) cells initially obtained 
from National Centre for Cell Sciences (NCCS), Pune 
(India) were maintained by regular intraperitoneal pas-
sage in Swiss mice.
In vitro screening in human and mouse tumor 
cell lines. Nap-NU, Napro-NU and 5-NO2-Nap-
NU were screened in human Jurkat (lymphoma) and 
mouse S-180, EC and Dalton Lymphoma-60 (DL-60) 
cell lines by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay [10]. Drug stock 
solutions (20 mg/ml) were prepared in DMSO. These 
were serially 10-fold diluted with complete sterile 
RPMI-1640 medium prior to use to obtain different 
drug concentrations. Standard drugs as CCNU and 
5-fluorouracil (5-FU) were also included. Cell suspen-
sion (100 μl) from the stock (2×105 cells per well) were 
added to 96-well cell culture plates and incubated with 
drug solutions (10 μl) of different concentrations for 
48 hrs. All vehicle controls contained the same concen-
tration of DMSO. After removal of 100 μl of media from 
each well, 10 μl of a 5 mg/ml solution of MTT in Dul-
becco’s PBS (GIBCO, BRL) were added and incubated 
for 4 hr at 37 °C. Subsequently, acid isopropanol so-
lution (100 μl, 0.04 N HCl in isopropanol) was added 
to the wells to dissolve formed formazan crystals. 
Optical density was measured in a microplate reader 
(BioTek Instruments Inc., Vermont, USA) at 540 nm.
Effect on blood mononuclear cells (MNC). 
MNC was isolated from heparinized venous blood 
obtained from healthy mouse by Ficoll-Paque (His-
topaque 1077, Sigma Aldrich Inc., USA) density gra-
dient centrifugation as per standard procedure [11]. 
MNCs (1×105 cells/well) were cultured in complete 
RPMI-1640 media as usual and incubated with Nap-
NU, Napro-NU and 5-NO2-Nap-NU for 48 h followed 
by MTT assay [10].
In vivo screening in solid mouse tumors. Mice 
were inoculated subcutaneously in the hindquarter 
with 2×106 viable S-180 cells on day 0. Nap-NU, 
Napro-NU and 5-NO2-Nap-NU were administrated 
in two schedules, either early treatment QD1–7 or late 
treatment QD5–11 on post tumor inoculation phase. 
In both schedules, drug solutions were administrated 
at its optimum dose of 50 mg/kg dose for seven days 
continuously, keeping CCNU (50 mg/kg) as positive 
control. Growth of solid tumor was monitored weekly 
by caliper measurement and survival was noted daily. 
Tumor volume (in mm3) was calculated using the stan-
dard formula: (width2 × length)/2 [12].
In a similar fashion, three nitrosoureas were tested 
in EC solid tumor model, inoculating 1×107 viable 
EC cells subcutaneously in the hindquarter on day 0. 
Then test drug (50 mg/kg) and positive control 
5-FU were injected for 7 days. Percent tumor growth 
inhibition and mortality were calculated from the ob-
served data.
Apoptosis analysis. Apoptosis was analysed us-
ing Annexin V — Propidium Iodide (PI) apoptosis de-
tection kit (BD Pharmingen, San Diego, USA), accord-
ing to manufacturer’s protocol. S-180 cells in complete 
RPMI media (2 × 105 cells/100 μl) were seeded in six 
well plates. Nap-NU, Napro-NU, 5-NO2-Nap-NU and 
CCNU (10 μl in volume) in DMSO at different concen-
trations were added to wells followed by the addition 
of required media (total volume 1 ml). It was incubated 
for 24 h at 37 °C. The cells were centrifuged at room 
temperature at 1500 rpm for 5 min. The pellet was 
washed twice with cold PBS and was re-suspended 
in the binding buffer (1X, 100 μl) provided. The cells 
were stained with Annexin V-FITC (5 μl) and PI (5 μl) 
and incubated for 15 min in the dark at 25 °C. Finally, 
binding buffer (400 μl) was added to each tube and 
flow cytometrically analyzed (FACSCaliber, Becton 
Dickinson, Mountainview, CA) using Cell Quest soft-
ware [13].
Assessment of metabolic and immune to-
xicities. The optimum dose of Nap-NU and 5-NO2-
Nap-NU (50 mg/kg) were administered in normal 
and S-180 bearing mice from day 1 to day 7 (QD1–7), 
keeping one untreated group in each case. Livers 
and kidneys were collected from normal and sarcoma 
(untreated and treated) bearing mice for histological 
analysis. Tissues were fixed in 10% formal saline and 
paraffin sections were prepared for Hematoxylin and 
Eosin (H & E) staining. The histopathological changes 
were evaluated by bright field microscopy [12] and 
photographed.
Flow cytometric analysis for surface phenotypic 
markers of blood MNC was performed after purifica-
tion of MNC from blood collected from S-180 solid tu-
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mor bearing control and treated mice [both early treat-
ment QD1–7 or late treatment QD5–11] on day 27. MNCs 
(5×105 cells) were labeled with 20 μl of fluorescence 
labeled antibodies (CD4-FITC, CD8-PE and CD25-PE) 
for 30 min. After labeling, cells were washed in FACS 
buffer (PBS with 1% FBS), fixed in 1% paraformalde-
hyde in PBS, and cytometry was performed (FACS-
Caliber, Becton Dickinson, Mountainview, CA) [14].
RESULTS
Cytotoxicity screening in human and murine tu-
mor cell lines. Screening of Nap-NU, Napro-NU and 
5-NO2-Nap-NU, in murine S-180, EC and DL-60 cell 
lines and in human Jurkat lymphoma by MTT assay 
revealed considerable tumor cell inhibition at dif-
ferent concentration (Fig. 2, a–d). In S-180 cell line 
the compounds showed cytotoxicity at 50 μM concen-
trations (Fig. 2, a). Three derivatives inhibited EC cells 
at 50 μM doses and that was more or less same in com-
parison to CCNU and 5-FU (Fig. 2, b). In DL-60 cell line 
percentage of inhibition by Nap-NU at 50 μM was al-
most equal compare to CCNU and in Jurkat lymphoma 
observed cytotoxicity by 5-NO2-Nap-NU was more 
than both CCNU and 5-FU (Fig. 2, c, d). Interestingly, 
the compounds have shown minimum cytotoxicity 
to MNCs for mouse blood at the same dose (data not 
shown).
Restriction of solid sarcoma growth and 
increases survivability. The growth responses 
in S-180 and EC solid tumors were assessed following 
drug treatment at the optimum dose (50 mg/kg for 
day 1–7). It was worthy to note that three compounds 
have significantly prolonged life span of S-180 tumor 
bearing mice with 3/6 animals having survival rates of 
> 100 days and also the tumor volume of treated mice 
was significantly reduced in comparison to control 
(Fig. 3, a). In vivo experiments in EC with this optimum 
dose furnished comparable results having 50% tumor 
growth inhibition (Table 1). It is interesting to note that 
tumor volume was significantly reduced and also 2 out 
of 6 mice were completely cured having > 80 days sur-
vivability in comparison to control group bearing highly 
advanced 5 days tumor (Fig. 3, b). It was also found 
that CCNU had exhibited highly significant antican-
cer activity in these tumor systems having significant 
tumor growth inhibition (Fig. 3, a, b). However, survi-
vability was observed to be less than test compounds, 
possibly imparting some degree of toxicity. 5-FU was 
simultaneously assessed in EC having 50% tumor 
growth inhibition (see Table 1).
Table 1. In vivo anti-tumoral screening of Nap-NU, Napro-NU and 5NO2N-
ap-NU in EAC solid tumor
Treatment 
Groups
Average body weight, g Average tu-
mor weight 
on 13th day, 
mg
Tumor 
growth in-
hibition,
%
Mor-
tality1 5 9 13
Nap-NU 24.57 24.00 22.42 22.14 565.42 49.60 −
Napro-NU 24.85 24.14 23.00 21.85 654.88 41.63 −
5-NO2-Nap-NU 25.00 23.00 20.42 20.50 800.64 28.64 −
5-FU 25.14 24.14 22.85 22.17 531.34 52.64 0/7
Untreated 24.80 25.74 26.10 28.33 1122.00 − 0/10
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Fig. 2. In vitro cytotoxic efficacy of Nap-NU, Napro-NU and 
5-NO2-Nap-NU against tumor cell lines by MTT assay; a — mouse 
sarcoma cells (S-180); b — mouse carcinoma cells (EC); c — 
mouse lymphoma cell (DL-60); d — T cell lymphoma (Jurkat) 
cell lines. Cells were seeded at 2×105 cells per well in 96-well 
cell culture plates and incubated with Nap-NU, Napro-NU and 
5-NO2-Nap-NU solutions for 48 h. Each point represents M ± 
SD of three separate experiments (p < 0.05).
Cytotoxicity to cancer cells by inducing apoptosis. 
S-180 cells were treated with Nap-NU, Napro-NU and 
5-NO2-Nap-NU, stained with annexin V–FITC/PI. It was 
apparent from Fig. 4, a that the number of late apoptotic 
cells (AnnV+PI+) was higher in the case of sarcoma cells 
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treated with Nap-NU (10.61% at 50 μM) in comparison 
to CCNU (6.79%). In view of Fig 4, b, c in comparison 
to standard drugs CCNU, at 50 μM the number of late 
apoptotic cells (AnnV+PI+) were higher in Napro-NU 
(30.54%) and 5-NO2-Nap-NU (12.76%).
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Fig. 3. In vivo anti-tumoral screening of Nap-NU, Napro-NU and 
5-NO2-Nap-NU in S-180 solid tumor in QD1–7 (a) or late treatment 
QD5–11 (b). Mice were inoculated subcutaneously with 2×106 vi-
able sarcoma cells on day 0. The derivatives were administrated 
in treatment schedules QD1–7 (a) and QD5–11 (b) on post tumor 
inoculation phase. Tumor volume (mm3) was calculated using 
the standard formula: (width2 × length)/2. p < 0.01 obtained 
from three experiments
Histopathological analysis of liver and kidney
Histology of liver. Treatment with Nap-NU. Nor-
mal control (NC) group: histology of liver of normal 
mouse showed normal architecture having a distinct 
central vein within a lobule and a portal area consisting 
of interlobular branch of portal vein, bile duct, branch 
of a hepatic artery and interlobular septum (Fig. 5, a).
S-180 control (SC) group: Histology of liver 
of SC mouse (14th day) showed hyperactive Kupffer 
cells and lymphocyte infiltration in areas adjacent 
to central vein (Fig. 5, e–g).
Normal mice treated with Nap-NU (NT) group and 
S-180 mice treated with Nap-NU (ST) group: It was ob-
served that liver sections of mice in these groups showed 
few inflammatory cells and hyperactive Kupffer cells on the 
day 9th (Fig. 5, b, h). On the day 14th, focal necrosis was 
observed at some region in both the groups (Fig. 5, c, 
i). In ST group, infiltration of lymphocytes was observed 
in lower numbers relative to SC mice (Fig. 5, h–j). Also 
the activation of Kupffer cells was enhanced compared 
to the day 9th. On the day 19th, a large number of regener-
ated hepatocytes were observed on the liver parenchyma. 
Infiltration of lymphocytes in both the treated groups was 
minimum and Kupffer cell activity was normal (Fig. 5, d, j).
Treatment with 5-NO2-Nap-NU. NC group: histo l ogy 
of liver of NC mouse showed normal architecture having 
a distinct central vein within a lobule and a portal area 
consisting of interlobular branch of portal vein, bile duct, 
branch of a hepatic artery and interlobular septum.
SC group: Histology of liver of SC mouse (14th day) 
showed hyperactive Kupffer cells and lymphocyte 
infiltration in areas adjacent to central vein.
Photomicrographs of liver of ST group of mice treated 
with 5-NO2-Nap-NU showed normal histology (data not 
shown).
Hepatotoxicity resulting from administration of a sin-
gle dose of CCNU was studied by weekly determinations 
of liver function tests and performance of precutaneous 
liver biopsies [15].
Histology of kidney. Treatment with Nap-
NU. In NC group renal cortex contains glomeruli, blood 
vessels, tubules and interstitium. In the cortex but not 
the medulla, the tubules are almost back to back, i.e., 
the tubular basement membranes are almost to uching 
(Fig. 5, k). Photomicrographs of kidney of NC, NT and 
ST mice showed normal histology (Fig. 5, l–q). The cortex 
contained well-disposed renal corpuscles (i.e., intact 
Bowman’s capsule and glomerulus), convoluted tubules 
and medullary rays. The inner medulla region contained 
the Henle’s loop and the collecting tubules (Fig. 5, l–q).
Treatment with 5-NO2-Nap-NU. Photomicrographs 
of kidney of SC, ST and NT groups of mice treated 
with 5-NO2-Nap-NU showed normal histology (data 
not shown).
CCNU nephrotoxicity have been reported in cancer 
patients having astrocytoma of the brain [16].
Non-cytotoxic to normal blood lymphocytes, 
including T cells. It was of interest to know the effect 
of Nap-NU, Napro-NU and 5-NO2-Nap-NU on circulat-
ing T lymphocytes when drug was administered in vivo 
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in sarcoma bearing mice. It was apparent from Fig. 6 that 
Nap-NU had no adverse effect on CD4+ and CD8+ T cells. 
On the other hand, percentage of CD4+ CD25+ suppres-
sor regulatory cells was decreased after drug treatment, 
though it was not statistically significant (Fig. 6, a–f). 
In CCNU treated mice no such stimulatory effect was 
observed (data not shown). Napro-NU and 5-NO2-Nap-
NU also showed immunostimulatory functions (Table 2).
Table 2. Expression status of CD4+, CD8+ and CD25+ on MNC of Napro-
NU and 5-NO2-Nap-NU
Treatment 
day Cell Types
Positive cells, %
Unstain Control Napro-NU 5-NO2-Nap-NU CCNU
1–7
CD4+ 0.70 42.46 45.01 48.51 50.04
CD8+ 0.38 20.42 21.32 22.03 22.10
CD4+CD25+ 0.06 21.22 22.52 18.36 20.56
5–11
CD4+ 0.00 10.05 12.14 12.57 15.07
CD8+ 1.84 26.61 30.11 33.12 30.10
CD4+CD25+ 0.00 11.20 12.37 12.81 13.94
DISCUSSION
In our effort to develop new nitrosourea compounds, 
we have developed a series of compounds and assessed 
their antitumor activity [7–9, 17, 18]. Among them Nap-
NU, Napro-NU and 5-NO2-Nap-NU were examined 
in in vitro as well as in vivo for their tumor lytic effects, and 
most promising results, in comparison to standard chemo-
therapeutic agents (CCNU, 5-FU), have been observed. 
Examination of cytotoxic potential of above three 
NU’s in different human and mouse cancer cell line 
revealed their considerable cytotoxicity comparable 
to CCNU and 5-FU. However, in SNB-78, HOP-62, 
 HL-60 and U-937 cells, the compounds showed 
gre ater cytotoxicity than standard chemotherapeu-
tic drugs as determined by SRB and MTT assays. 
In vivo toxicological assay conducted in normal and 
S-180 bearing mice revealed that these are well tole-
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Fig. 4. Analysis of apoptosis induced by Nap-NU (a), Napro-NU (b) and 5-NO2-Nap-NU (c) in sarcoma cells (2×105 cells/100 μl) 
by flow cytometry using annexin V-FITC and PI. Quadrant analysis of fluorescence intensity of gated cells in FL-1 (annexin V-FITC) 
and FL-2 (PI) channels. Three NU’s at 50 μM induces apoptosis of sarcoma cells in greater extent than CCNU
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rated in mice and did not adversely  affect hematopoi-
esis at their optimum doses. CCNU produced delayed 
and cumulative bone marrow depression, which signi-
ficantly limits its chemical usefulness [19]. In the light 
of those promising results, presently the experimenta-
tion was extended to two solid tumor models. It was 
found that Nap-NU, Napro-NU and 5-NO2-Nap-NU in-
duced significant retardation of these tumors grown 
in Swiss mice. The compounds not only restricted 
the early growth, they also effectively inhibited the tu-
Fig. 5. Histological features of liver and kidney after Nap-NU treatment in mice. Nap-NU (50.0 mg/kg) was administered in normal and 
S-180 bearing mice from day 1–7th. After the completion of the treatment, animals were sacrificed on the day 9th, 14th & 19th. Liver and 
kidney were collected to be analyzed histopathologically. Photomicrograph of H & E stained section of liver: (a) Normal control (NC) 
mouse, (b–d) Normal treated (NT) mouse, (e–g) S-180 control (SC) mouse, (h–j) S-180 treated (ST) mouse at the day 9th, 14th, 19th (× 
200). Kidney: (k) Normal control (NC) mouse, (l–m) Normal treated (NT) mouse, (n–o) S-180 control (SC) mouse, (p–q) S-180 treated 
(ST) mouse at the day 9th, 14th (× 200)
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Fig. 6. Assessment of immune toxicities of Nap-NU in S-180 solid tumor. Mice were inoculated subcutaneously with 2 × 106 viable 
sarcoma cells on day 0. Nap-NU was administrated in QD1–7 (a–c) or QD5–11 schedules (d–f) after tumor inoculation. After the purifica-
tion of MNC, blood was collected from both groups. MNCs (5 × 105 cells) were labeled with 20 μl of fluorescence labeled antibodies 
(CD4-FITC, CD8-PE and CD25-PE) for 30 min. Nap-NU maintained CD4+, CD8+ T cell and CD4+CD25+ Treg cell status in Sarcoma 
bearing mice. Data are presented as the means ± SD
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mor growth in advanced state. Interestin gly, life span 
of Nap-NU, Napro-NU and 5-NO2-Nap-NU treated 
S-180 bearing mice was more than that observed 
in case of CCNU. Based on our early experiment 
in vivo system it can be realized that hematotoxic 
and nephrotoxic effect of these tested compounds 
have been lass than CCNU. This is possibly reason 
of greater life span of NU’s treated mice than those 
received CCNU. It also induced apoptosis of sarcoma 
cells to a greater extent than CCNU. This observation 
helped to understand the efficacy of these deriva-
tives to kill the tumor cells. Tumor burden itself alters 
normal physiology that was reflected in the histology 
of li vers and kidneys of tumor host. After chemotherapy 
the toxic effect like unfavorable changes in hemato-
logical parameters, bone-marrow suppression, etc., 
observed sometimes. In continuation to earlier report 
of minimum toxicity of these NU compounds, here, 
we have examined whether they have any toxic ef-
fect that could be demonstrated by histopathological 
analysis. These NU compounds helped to norma lize 
the tumor induced alteration of liver and kidney architec-
ture and such normalizing effect is more prominent than 
CCNU. Moreover, in normal mice, the compounds have 
shown no effect on normal liver and kidney histo logy. 
In vivo effect of the compounds on liver enzymes and 
different kidney components were studied before [7–9] 
and no significant abnormalities were noted. Study was 
also extended to find its effect on important immune 
cells, i.e., T lymphocytes. It had no cytotoxic effect 
on CD4+ and CD8+ T cells; interestingly it regulated 
suppressor Treg cells. This observation suggested 
that Nap-NU, Napro-NU and 5-NO2-Nap-NU helped 
to maintain the normal immune functions of the host. 
Thus, this group of drugs might act perfectly and clini-
cal outcome would be facilitated. The, antimetastatic 
activity of the compounds will be tested in future.
Thus, data obtained from this study holds promise 
of Nap-NU, Napro-NU and 5-NO2-Nap-NU as antican-
cer agent for treating various types of tumors. Further 
preclinical study is pre-requisite to move forward with 
this promising drug to the clinic.
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